Sarepta Therapeutics | SRPT - Gross Profit On Sales


Sarepta Therapeutics reported $247.9M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.68B 358.6M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Incyte USD 1.27B 130.22M Sep/2025
Insmed USD 111.44M 33.36M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Moderna USD 809M 791M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025